相关实验视频
Updated: Jul 25, 2026
09:39
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
概括
追溯研究可能会高估第一季度伊特拉科纳暴露的先天性形风险. 预期确定显示了明显较低的比率,突出显示了旧数据中的潜在报告偏差.
科学领域:
- 药物监督 药物监督 药物监督
- 生殖毒理学 生殖毒理学
- 临床流行病学临床流行病学
背景情况:
- 第一个三个月内接触某些药物可能会带来先天性形的风险.
- 伊特拉科纳是一种抗真菌剂,其在怀孕早期的安全性需要仔细评估.
- 以前关于药物暴露和出生缺陷的研究通常依赖于回顾性数据,这些数据可能会受到偏见.
研究的目的:
- 用前性与后性确定方法比较在第一季度暴露于伊特拉科纳后的先天性形的发生率.
- 评估确定方法对与伊特拉可纳相关的出生缺陷报告风险的影响.
主要方法:
- 一个对先天性形率的比较分析.
- 使用前性和后性数据收集,用于暴露于伊特拉科纳后的怀孕结果.
- 统计分析以确定观察到的差异的意义 (提供p值).
主要成果:
- 遗传形的发生率在回顾性确定 (13.0%) 与前性确定 (3.2%) 相比显著更高.
- 观察到的差异具有统计学意义 (p=0.006),这表明当数据被追溯收集时,风险增加了四倍.
- 这表明回顾性研究中存在大量报告偏差.
结论:
- 在药监测研究中,回顾性数据收集可能会导致对不良事件率的高估,例如先天性形.
- 前性研究提供了更可靠的数据来评估怀孕期间伊特拉科纳等药物的安全性.
- 调查结果强调了在解释历史或回顾性研究数据时承认和考虑报告偏差的重要性.
相关概念视频
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:20Drug Product Performance: In Vitro–In Vivo Correlation
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...